Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro

Clinical and Experimental Immunology

Volumn 119, Issue 2, 2000, Pages 299-304

  Brodskyn, C ^a,b   Beverley, S M ^c   Titus, R G ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

IL 12; Leishmania major; Macrophages; Th1; Th2

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 5;

AMASTIGOTE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; LEISHMANIA MAJOR; MACROPHAGE; PARASITE IMMUNITY; PARASITE SURVIVAL; PARASITE VIRULENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

ANIMALS; CELLS, CULTURED; CYTOKINES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-5; LEISHMANIA MAJOR; TETRAHYDROFOLATE DEHYDROGENASE; TH1 CELLS; TH2 CELLS; THYMIDYLATE SYNTHASE; VIRULENCE;

EID: 0033969991     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01122.x     Document Type: Article

References (26)

1. Barral-Netto M, Machado P, Bittencourt AL, Barral A. Recent advances in pathophysiology and treatment of human cutaneous leishmaniasis. Curr Opin Dermatol 1997; 4:51-8.
2. Carvalho EM, Correia Filho D, Bacellar O, Almeida RP, Rocha E. Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. Am J Trop Med Hyg 1995; 53:273-7.
3. Titus RG, Gueiros-Filho FJ, Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 92 1995; 92:10267-71.
4. Shankar AH, Titus RG. Leishmania-major-specific, CD4+, major histocompatibility complex class II-restricted T cells derived from lymphoid tissues of naive mice. J Exp Med 1993; 78:101-11.
5. Veras P, Brodskyn CI, Balestieri FM, Freitas LAR, Ramos APS, Queiroz ARP, Beverly SM, Barral-Netto MA. dhfr-ts Leishmania Major Knockout Mutant Cross Protects Against Leishmania Amazonensis. Memorias do Instituto Osvaldo Cruz 1999; 94:491-6.
6. Titus RG, Muller I, Kimsey P, Cerny A, Behin R, Zinkernagel RM, Louis JA. Exacerbation of experimental murine cutaneous leishmaniasis with CD4+ Leishmania major-specific T cell lines or clones which secret IFN-γ and mediate parasite-specific delayed-type hypersensitivity. Eur J Immunol 1991; 21:559-67.
7. Goldroen MH, Gannon PJ, Lutz M, Holyoke ED. Isolation of human peripheral blood lymphocytes: Modification of a double discontinuous density gradient of Ficoll-Hypaque. J Immunol Methods 1977; 14:15-7.
8. Russo DM, Chakrabarti P, Burns JM. Naive human T cells develop into Th1 or Th0 effectors and exhibit cytotoxicity early after stimulation with Leishmania-infected macrophages. J Infect Dis 1998; 77:1345-51.
9. Subauste CS, Fuh F, De Waal M, Remington JS. Alpha beta T cell response to Toxoplasma gondii in previously individuals. J Immunol 1998; 160:3403-11.
10. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997; 6:541-9.
11. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91:1390-5.
12. Russo DM, Burns JM, Carvalho EM, Armitage RJ, Grabstein KH, McMaster WR, Reed SG. Human T cells response to gp63, a surface antigen of Leishmania. J Immunol 1991; 147:3575-80.
13. Barral A, Teixeira M, Reis P et al. Transforming growth factor beta in human cutaneous leishmaniasis. Am J Pathol 1995; 147:947-54.
14. Barral-Netto M, Badaro R, Barral A et al. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infec Dis 1991; 163:853-7.
15. Scharston-Kersten T, Scott P. The role of innate immune response in Th1 cell development following Leishmania major infection. J Leuk Biol 1995; 57:515-22.
16. Sypek JP, Chung CL, Mayor SE et al. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type I immune response. J Exp Med 1993; 177:1797-802.
17. Reiner SL, Zheng S, Wang ZE, Stowring L, Locksley RM. Leishmania promastigotes evade interleukin 12 (IL-12) and stimulate a broad range of cytokines from CD4+ T cells during initiation of infection. J Exp Med 1994; 179:447-56.
18. Scharston-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer activation and subsequent development in experimental leishmaniasis. J Immunol 1995; 154:5320-30.
19. Murray HW, Hariprashad J, Coffman RL. Behavior of visceral Leishmania donovani in an experimentally induced T helper 2 (Th2)-associated response model. J Exp Med 1997; 185:867-74.
20. Heinzel FP, Rerko RM, Ahmed F, Pearlman E. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995; 155:730-9.
21. Heinzel FP, Rerko RM, Hatam F, Locksley RM. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol 1993; 150:3924-31.
22. Wang ZE, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL, Locksley RM. Interferon-γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994; 91:12932-6.
23. Afonso LC, Scahrton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin 12 in a vaccine against Leishmania major. Science 1994; 263:235-7.
24. Carrera L, Gazzinelli RT, Badolato R, Hieny S, Muller W, Kuhn R, Sacks DL. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J Exp Med 1996; 183:515-26.
25. Seguin R, Kasper LH. Sensitized lymphocytes and CD40 ligation augment interleukin 12 production by human dendritic cells in response to Taxoplasma gondii. J Infec Dis 1999; 179:467-74.
26. Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993; 61:2952-7.